Download PDF
Thromb Haemost 2014; 111(01): 183-188
DOI: 10.1055/s-0037-1608912
Editors’ Choice
Schattauer GmbH

Editors’ Choice papers in Thrombosis and Haemostasis

Christian Weber
1   Institute for Cardiovascular Prevention, Ludwig-Maximilians-University, Munich, Germany
,
Gregory Y. H. Lip
2   University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
› Author Affiliations
Further Information

Publication History

Publication Date:
15 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Weber C, Lip GYH. Highlights and hot topics from 2011 in Thrombosis and Haemostasis. Thromb Haemost 2012; 107: 196-199.
    Thieme ConnectPubMedSearch in Google Scholar
  • 2 Weber C, Lip GYH. Editors’ Choice papers in Thrombosis and Haemostasis. Thromb Haemost 2013; 109: 170-173.
    Thieme ConnectPubMedSearch in Google Scholar
  • 3 Turpie AG, Kreutz R, Llau J. et al. Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor. Thromb Haemost 2012; 108: 876-86.
    Thieme ConnectPubMedSearch in Google Scholar
  • 4 Marín F, Huber K, Lip GY. Antithrombotic therapy in atrial fibrillation and stent implantation: treatment or threats by the use of triple or dual anti-thrombotic therapy. Thromb Haemost 2013; 110: 623-625.
    Thieme ConnectPubMedSearch in Google Scholar
  • 5 Faxon DP, Eikelboom JW, Berger PB. et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011; 106: 572-584.
    Thieme ConnectPubMedSearch in Google Scholar
  • 6 Lip GY, Andreotti F, Fauchier L. et al. European Heart Rhythm Association. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 2011; 106: 997-1011.
    Thieme ConnectPubMedSearch in Google Scholar
  • 7 De Caterina R, Husted S, Wallentin L. et al. General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 109: 569-579.
    Thieme ConnectPubMedSearch in Google Scholar
  • 8 De Caterina R, Husted S, Wallentin L. et al. Vitamin K antagonists in heart disease: Current status and perspectives (Section III). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease Thromb Haemost 2013; 110: 1087-1107.
    PubMedSearch in Google Scholar
  • 9 Wilke T, Groth A, Mueller S. et al. Oral anticoagu-lation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anti-coagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients. Thromb Haemost 2012; 107: 1053-1065.
    Thieme ConnectPubMedSearch in Google Scholar
  • 10 Sorensen SV, Kansal AR, Connolly S. et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost 2011; 105: 908-919.
    Thieme ConnectPubMedSearch in Google Scholar
  • 11 Olesen JB, Lip GY, Lindhardsen J. et al. Risks of thromboembolism and bleeding with thrombo-prophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost 2011; 106: 739-749.
    Thieme ConnectPubMedSearch in Google Scholar
  • 12 Huisman MV, Lip GY, Diener HC. et al. Dabi- gatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012; 107: 838-847.
    Thieme ConnectPubMedSearch in Google Scholar
  • 13 Mantha S, Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost 2012; 108: 476-484.
    Thieme ConnectPubMedSearch in Google Scholar
  • 14 Olesen JB, Torp-Pedersen C, Hansen ML. et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost 2012; 107: 1172-1179.
    Thieme ConnectPubMedSearch in Google Scholar
  • 15 Neubeck L, Redfern J, Freedman SB. Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost 2013; 110: 213-222.
    Thieme ConnectPubMedSearch in Google Scholar
  • 16 Violi F, Perri L, Loffredo L. Should all acutely ill medical patients be treated with antithrombotic drugs? A review of the interventional trials. Thromb Haemost 2013; 109: 589-595.
    Thieme ConnectPubMedSearch in Google Scholar
  • 17 Ferrandis R, Castillo J, de Andrés J. et al. The perioperative management of new direct oral anticoagulants: a question without answers. Thromb Haemost 2013; 110: 515-522.
    Thieme ConnectPubMedSearch in Google Scholar
  • 18 Desai J, Kolb JM, Weitz JI. et al. Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies. Thromb Haemost 2013; 110: 205-212.
    Thieme ConnectPubMedSearch in Google Scholar
  • 19 Banerjee A, Lane DA, Torp-Pedersen C. et al. Net clinical benefit of new oral anticoagulants (dabi-gatran, rivaroxaban, apixaban) versus no treat- ment in a ‘real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012; 107: 584-589.
    Thieme ConnectPubMedSearch in Google Scholar
  • 20 Lindahl TL, Baghaei F, Blixter IF. et al. Expert Group on Coagulation of the External Quality Assurance in Laboratory Medicine in Sweden. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011; 105: 371-378.
    Thieme ConnectPubMedSearch in Google Scholar
  • 21 Samama MM, Contant G, Spiro TE. et al. Riva-roxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories. Evaluation of the anti-factor Xa chromogenic assay for the measurement of riva-roxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012; 107: 379-387.
    Thieme ConnectPubMedSearch in Google Scholar
  • 22 Douxfils J, Mullier F, Robert S. et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012; 107: 985-997.
    Thieme ConnectPubMedSearch in Google Scholar
  • 23 Omran H, Bauersachs R, Rübenacker S, Goss F, Hammerstingl C. The HAS-BLED score predicts bleedings during bridging of chronic oral antico-agulation. Results from the national multicentre BNK Online bRiDging REgistRy (BORDER). Thromb Haemost 2012; 108: 65-73.
    Thieme ConnectPubMedSearch in Google Scholar
  • 24 Diener HC. Pro: “The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation”. Thromb Haemost 2013; 110: 493-495.
    Thieme ConnectPubMedSearch in Google Scholar
  • 25 Stöllberger C, Finsterer J. Contra: “New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation”. Thromb Haemost 2013; 110: 496-500.
    Thieme ConnectPubMedSearch in Google Scholar
  • 26 Strüβmann T, Tillmann S, Wirtz T. et al. Platelets are a previously unrecognised source of MIF. Thromb Haemost 2013; 110: 1004-1013.
    Thieme ConnectPubMedSearch in Google Scholar
  • 27 Winkler J, Rand ML, Schmugge M. et al. Omi/ HtrA2 and XIAP are components of platelet apop-tosis signalling. Thromb Haemost 2013; 109: 532-539.
    Thieme ConnectPubMedSearch in Google Scholar
  • 28 Zhang Y, Liu X, Liu L. et al. Contact- and agonist-regulated microvesiculation of human platelets. Thromb Haemost 2013; 110: 331-339.
    Thieme ConnectPubMedSearch in Google Scholar
  • 29 Berger JS, Becker RC, Kuhn C. et al. Hyperreactive platelet phenotypes: relationship to altered serotonin transporter number, transport kinetics and intrinsic response to adrenergic co-stimulation. Thromb Haemost 2013; 109: 85-92.
    PubMedSearch in Google Scholar
  • 30 Navarro-Núñez L, Langan SA, Nash GB. et al. The physiological and pathophysiological roles of platelet CLEC-2. Thromb Haemost 2013; 109: 991-998.
    Thieme ConnectPubMedSearch in Google Scholar
  • 31 Stevic I, Chan HH, Chander A. et al. Covalently linking heparin to antithrombin enhances pro-thrombinase inhibition on activated platelets. Thromb Haemost 2013; 109: 1016-1024.
    Thieme ConnectPubMedSearch in Google Scholar
  • 32 Tan X, Shi J, Fu Y. et al. Role of erythrocytes and platelets in the hypercoagulable status in poly-cythemia vera through phosphatidylserine exposure and microparticle generation. Thromb Haemost 2013; 109: 1025-1032.
    Thieme ConnectPubMedSearch in Google Scholar
  • 33 Peter K. Isoform-specific effects of protein phos-phatase 1 on outside-in signalling of integrin aIIbβ3: a story told by genetic manipulation of platelet surrogate cells. Thromb Haemost 2013; 109: 7.
    Thieme ConnectPubMedSearch in Google Scholar
  • 34 Hosokawa K, Ohnishi T, Sameshima H. et al. Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions. Thromb Haemost 2013; 109: 102-111.
    Thieme ConnectPubMedSearch in Google Scholar
  • 35 Saucedo JF, Angiolillo DJ, DeRaad R. et al. SWAP Investigators. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. Thromb Haemost 2013; 109: 347-355.
    Thieme ConnectPubMedSearch in Google Scholar
  • 36 Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost 2011; 105 (Suppl. 01) S13-33.
    Thieme ConnectPubMedSearch in Google Scholar
  • 37 Hayon Y, Dashevsky O, Shai E. et al. Platelet lysates stimulate angiogenesis, neurogenesis and neu-roprotection after stroke. Thromb Haemost 2013; 110: 323-330.
    Thieme ConnectPubMedSearch in Google Scholar
  • 38 de Stoppelaar SF, Van’t Veer C, van den Boogaard FE. et al. Protease activated receptor 4 limits bacterial growth and lung pathology during late stage Streptococcus pneumoniae induced pneumonia in mice. Thromb Haemost 2013; 110: 582-592.
    Thieme ConnectPubMedSearch in Google Scholar
  • 39 Grove EL, Hossain R, Storey RF. Platelet function testing and prediction of procedural bleeding risk. Thromb Haemost 2013; 109: 817-824.
    Thieme ConnectPubMedSearch in Google Scholar
  • 40 Brouwer MA, Jaspers Focks J, Verheugt FW. High platelet reactivity--the challenge of prolonged anti-coagulation therapy after ACS. Thromb Haemost 2013; 109: 799-807.
    Thieme ConnectPubMedSearch in Google Scholar
  • 41 Hohlfeld T, Saxena A, Schrör K. High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs--pharmacological mechanisms and clinical relevance. Thromb Haemost 2013; 109: 825-833.
    Thieme ConnectPubMedSearch in Google Scholar
  • 42 McFadyen JD, Jackson SP. Differentiating haemo-stasis from thrombosis for therapeutic benefit. Thromb Haemost 2013; 110: 859-867.
    Thieme ConnectPubMedSearch in Google Scholar
  • 43 Karshovska E, Weber C, von Hundelshausen P. Platelet chemokines in health and disease. Thromb Haemost 2013; 110: 894-902.
    Thieme ConnectPubMedSearch in Google Scholar
  • 44 Verschoor A, Langer HF. Crosstalk between platelets and the complement system in immune protection and disease. Thromb Haemost 2013; 110: 910-919.
    Thieme ConnectPubMedSearch in Google Scholar
  • 45 Asare Y, Schmitt M, Bernhagen J. The vascular biology of macrophage migration inhibitory factor (MIF). Expression and effects in inflammation, atherogenesis and angiogenesis. Thromb Haemost 2013; 109: 391-398.
    Thieme ConnectPubMedSearch in Google Scholar
  • 46 Goddard LM, Iruela-Arispe ML. Cellular and molecular regulation of vascular permeability. Thromb Haemost 2013; 109: 407-415.
    Thieme ConnectPubMedSearch in Google Scholar
  • 47 Esmon CT. Molecular circuits in thrombosis and inflammation. Thromb Haemost 2013; 109: 416-420.
    Thieme ConnectPubMedSearch in Google Scholar
  • 48 Björkqvist J, Jämsä A, Renné T. Plasma kallikrein: the bradykinin-producing enzyme. Thromb Haemost 2013; 110: 399-407.
    Thieme ConnectPubMedSearch in Google Scholar
  • 49 Waeckel L, Potier L, Richer C. et al. Pathophysiol-ogy of genetic deficiency in tissue kallikrein activity in mouse and man. Thromb Haemost 2013; 110: 476-483.
    Thieme ConnectPubMedSearch in Google Scholar
  • 50 Scroyen I, Hemmeryckx B, Lijnen HR. From mice to men - mouse models in obesity research: What can we learn?. Thromb Haemost 2013; 110: 634-640.
    Thieme ConnectPubMedSearch in Google Scholar
  • 51 Rega-Kaun G, Kaun C, Wojta J. More than a simple storage organ: Adipose tissue as a source of adipokines involved in cardiovascular disease. Thromb Haemost 2013; 110: 641-650.
    Thieme ConnectPubMedSearch in Google Scholar
  • 52 Morange PE, Alessi MC. Thrombosis in central obesity and metabolic syndrome: Mechanisms and epidemiology. Thromb Haemost 2013; 110: 669-680.
    Thieme ConnectPubMedSearch in Google Scholar
  • 53 de Boer OJ, Li X, Teeling P. et al. Neutrophils, neutrophil extracellular traps and interleukin-17 associate with the organisation of thrombi in acute myocardial infarction. Thromb Haemost 2013; 109: 290-297.
    Thieme ConnectPubMedSearch in Google Scholar
  • 54 Carbone F, Nencioni A, Mach F. et al. Pathophysi-ological role of neutrophils in acute myocardial infarction. Thromb Haemost 2013; 110: 501-514.
    Thieme ConnectPubMedSearch in Google Scholar
  • 55 Gao C, Xie R, Li W. et al. Endothelial cell phagocytosis of senescent neutrophils decreases procoagu-lantactivity. ThrombHaemost 2013; 109: 1079-1090.
    PubMedSearch in Google Scholar
  • 56 Leers MP, Keuren JF, Frissen ME. et al. The pro-and anticoagulant role of blood-borne phagocytes in patients with acute coronary syndrome. Thromb Haemost 2013; 110: 101-109.
    Thieme ConnectPubMedSearch in Google Scholar
  • 57 Shantsila E, Tapp LD, Wrigley BJ. et al. CXCR4 positive and angiogenic monocytes in myocardial infarction. Thromb Haemost 2013; 109: 255-262.
    Thieme ConnectPubMedSearch in Google Scholar
  • 58 Shantsila E, Tapp LD, Wrigley BJ. et al. Receptors to interleukin-6 and adhesion molecules on circulating monocyte subsets in acute myocardial infarction. Thromb Haemost 2013; 110: 340-348.
    Thieme ConnectPubMedSearch in Google Scholar
  • 59 Prinz N, Clemens A, Canisius K. et al. Endosomal NADPH-oxidase is critical for induction of the tissue factor gene in monocytes and endothelial cells. Lessons from the antiphospholipid syndrome Thromb Haemost 2013; 109: 525-531.
    Thieme ConnectPubMedSearch in Google Scholar
  • 60 Perzborn E, Gruber A, Tinel H. et al. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost 2013; 110: 162-172.
    Thieme ConnectPubMedSearch in Google Scholar
  • 61 Nieuwenhuizen L, Roosendaal G, Coeleveld K. et al. Haemarthrosis stimulates the synovial fibrino-lytic system in haemophilic mice. Thromb Haemost 2013; 110: 173-183.
    Thieme ConnectPubMedSearch in Google Scholar
  • 62 Hugenholtz GC, Meijers JC, Adelmeijer J. et al. TAFI deficiency promotes liver damage in murine models of liver failure through defective down-regulation of hepatic inflammation. Thromb Haemost 2013; 109: 948-955.
    Thieme ConnectPubMedSearch in Google Scholar
  • 63 Diaz JA, Alvarado CM, Wrobleski SK. et al. The electrolytic inferior vena cava model (EIM) to study thrombogenesis and thrombus resolution with continuous blood flow in the mouse. Thromb Haemost 2013; 109: 1158-1169.
    Thieme ConnectPubMedSearch in Google Scholar
  • 64 Peter K. Isoform-specific effects of protein phos-phatase 1 on outside-in signalling of integrin aIIbβ3: a story told by genetic manipulation of platelet surrogate cells. Thromb Haemost 2013; 109: 7.
    Thieme ConnectPubMedSearch in Google Scholar
  • 65 Hirsch E. Two signalling hands for uPAR. Thromb Haemost 2013; 109: 179.
    Thieme ConnectPubMedSearch in Google Scholar
  • 66 Hammerstingl C, Pötzsch B, Nickenig G. Resolution of giant left atrial appendage thrombus with rivaroxaban. ThrombHaemost 2013; 109: 583-584.
    PubMedSearch in Google Scholar
  • 67 Golder M, Mewburn J, Lillicrap D. In vitro and in vivo evaluation of the effect of elevated factor VIII on the thrombogenic process. Thromb Haemost 2013; 109: 53-60.
    Thieme ConnectPubMedSearch in Google Scholar
  • 68 Pählman LI, Mörgelin M, Kasetty G. et al. Antimicrobial activity of fibrinogen and fibrinogen-de rived peptides-- a novel link between coagulation and innate immunity. Thromb Haemost 2013; 109: 930-939.
    Thieme ConnectPubMedSearch in Google Scholar
  • 69 Soya K, Terasawa F, Okumura N. Fibrinopeptide A release is necessary for effective B: b interactions in polymerisation of variant fibrinogens with impaired A: a interactions. Thromb Haemost 2013; 109: 221-228.
    Thieme ConnectPubMedSearch in Google Scholar
  • 70 Lima MA, Viskov C, Herman F. et al. Ultra-low-molecular-weight heparins: precise structural features impacting specific anticoagulant activities. Thromb Haemost 2013; 109: 471-478.
    Thieme ConnectPubMedSearch in Google Scholar
  • 71 van Mens TE, Levi M, Middeldorp S. Evolution of Factor V Leiden. Thromb Haemost 2013; 110: 23-30.
    Thieme ConnectPubMedSearch in Google Scholar
  • 72 Luu NT, Glen KE, Egginton S. et al. Integrin-sub-strate interactions underlying shear-induced inhibition of the inflammatory response of endothe-lial cells. Thromb Haemost 2013; 109: 298-308.
    Thieme ConnectPubMedSearch in Google Scholar
  • 73 Montuori N, Cosimato V, Rinaldi L. et al. uPAR regulates pericellular proteolysis through a mechanism involving integrins and fMLF-receptors. Thromb Haemost 2013; 109: 309-318.
    Thieme ConnectPubMedSearch in Google Scholar
  • 74 Asare Y, Shagdarsuren E, Schmid JA. et al. En-dothelial CSN5 impairs NF-kB activation and monocyte adhesion to endothelial cells and is highly expressed in human atherosclerotic lesions. Thromb Haemost 2013; 110: 141-152.
    Thieme ConnectPubMedSearch in Google Scholar
  • 75 Ylä-Herttuala S, Bentzon JF, Daemen MJAP. et al. Stabilisation of atherosclerotic plaques. Thromb Haemost 2011; 106: 1-19.
    Thieme ConnectPubMedSearch in Google Scholar
  • 76 Vuilleumier N, Montecucco F, Spinella G. et al. Serum levels of anti-apolipoprotein A-1 auto-antibodies and myeloperoxidase as predictors of major adverse cardiovascular events after carotid endar-terectomy. Thromb Haemost 2013; 109: 706-715.
    Thieme ConnectPubMedSearch in Google Scholar
  • 77 Carbone F, Nencioni A, Mach F. et al. Evidence on the pathogenic role of auto-antibodies in acute cardiovascular diseases. Thromb Haemost 2013; 109: 854-868.
    Thieme ConnectPubMedSearch in Google Scholar
  • 78 Yuana Y, Bertina RM, Osanto S. Pre-analytical and analytical issues in the analysis of blood micropar-ticles. Thromb Haemost 2011; 105: 396-408.
    Thieme ConnectPubMedSearch in Google Scholar
  • 79 Hernández C, Orbe J, Roncal C. et al. Tissue factor expressed by microparticles is associated with mortality but not with thrombosis in cancer patients. Thromb Haemost 2013; 110: 598-608.
    Thieme ConnectPubMedSearch in Google Scholar
  • 80 Nazari-Jahantigh M, Wei Y, Schober A. The role of microRNAs in arterial remodelling. Thromb Haemost 2012; 107: 611-618.
    Thieme ConnectPubMedSearch in Google Scholar
  • 81 Kaudewitz D, Lee R, Willeit P. et al. Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease. Thromb Haemost 2013; 110: 609-615.
    Thieme ConnectPubMedSearch in Google Scholar